EPAM Systems
EPAM
$137.36
-0.59%
EPAM Systems is a global IT services and platform engineering firm that provides software development, product design, consulting, and digital transformation services to enterprise clients, operating within the Information Technology Services industry with roughly 62,850 employees and approximately 60% of revenue generated in North America. The company is a premium-tier, engineering-led disruptor in the IT services space, distinguished by its deep software-engineering DNA, its historical concentration of delivery talent in Central and Eastern Europe, and its positioning as a partner to Fortune 500 digital-native and platform businesses rather than a traditional low-cost outsourcer. The current investor narrative is dominated by the tension between EPAM's resilient revenue growth and a sharp reset in profitability expectations, with 2026 guidance that disappointed the market on growth and GAAP earnings, fueling an active debate over whether generative AI is a tailwind (driving client transformation spend) or a structural threat to billable headcount-based IT services models. Recent headlines capture this volatility vividly, including a 16% single-week selloff after weak 2026 guidance and a subsequent sharp recovery as investors reassessed the company's cash generation, aggressive buyback activity, and deeply compressed valuation.…
EPAM
EPAM Systems
$137.36
Related headlines
Investment Opinion: Should I buy EPAM Today?
Rating: Hold. EPAM is a high-quality, net-cash IT services franchise trading at a genuinely cheap forward multiple of 9.85x, but the stock has already rallied 27.59% in a month to $138.17, roughly 6.8% above the $128.71 average analyst target, while margins compress and free cash flow is negative — so the risk/reward is balanced rather than compelling at this price. The consensus of 8 Buy, 11 Hold and 0 Sell (recommendation mean 2.21) captures exactly this tension: no one is calling it a short, but the professional community is not chasing it here either.
Supporting evidence cuts both ways. On valuation, the forward PE of 9.85x against a trailing PE of 30.31x implies forward EPS of $15.05 versus a reported trailing EPS of $0.03, and the PS ratio of 2.10x and EV/Sales of 1.16x sit roughly 86% below the 14.84x PS the stock commanded in Q4 2023 — a multi-year low in the valuation band. On growth, Q2 2026 revenue of $1.415 billion grew only 4.53% year-over-year, though it rose sequentially from $1.400 billion in Q1 2026 and $1.394 billion in Q3 2025, so the base is holding rather than contracting. Profitability is the weak link: gross margin of 30.36% is down from 34.56% in Q3 2024, operating margin of 10.76% is down from 15.16%, and net margin of 7.28% is down from 11.68%, while Q2 2026 free cash flow was -$17.6 million after -$54.2 million in Q1 2026. The balance sheet is the offset — debt-to-equity of 0.039, a current ratio of 2.59 and $794.3 million of cash — and trailing twelve-month FCF of $482.6 million with ROE of 10.27% shows the business can still generate cash across a full cycle.
The thesis would break in either direction on specific triggers. On the downside, if gross margin slips below 30% and revenue growth stalls near zero, the 9.85x forward multiple is a value trap and the stock retests the $97 analyst low (about 30% downside) or the $73.06 52-week low (about 47% downside). On the upside, this Hold would upgrade to Buy if forward EPS of $15.05 is validated by reported results and gross margin stabilizes above 30%, or if the stock pulls back toward the $110-$115 consolidation zone, restoring upside to the $128.71 consensus target. It would downgrade to Sell if Q3 free cash flow stays negative for a third consecutive quarter or if revenue growth decelerates below 3%. Verdict: fairly valued to modestly undervalued on forward earnings, but no longer cheap on price after the rally — a watchlist name, not a chase.
Sign up to view all
EPAM 12-Month Price Forecast
The forward-looking picture is genuinely two-sided. On valuation, a 9.85x forward PE, 2.10x PS and 1.16x EV/Sales represent a roughly 86% de-rating from the 14.84x PS of Q4 2023, and a debt-to-equity of 0.039 with $794.3 million of cash means there is no solvency risk while the market waits for the earnings recovery. Against that, margins have compressed 400-440 basis points across gross, operating and net lines in under two years, free cash flow has been negative for two straight quarters, and the stock has already run 27.59% in a month to trade above the consensus target — so the easy money from the $73 capitulation low has been made. The 8 Buy / 11 Hold / 0 Sell distribution with a 2.21 recommendation mean reflects a community that sees the de-rating as overdone but is unwilling to underwrite the AI question yet. I would upgrade to bullish on a pullback toward the $110-$115 consolidation zone or on reported evidence that gross margin has bottomed above 30% with positive free cash flow; I would downgrade to bearish if gross margin breaks below 30% or revenue growth falls under 3%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on EPAM Systems's 12-month outlook, with a consensus price target around $131.24 and implied upside of -4.5% versus the current price.
Average Target
$131.24
19 analysts
Implied Upside
-4.5%
vs. current price
Analyst Count
19
covering this stock
Price Range
$99 - $200
Analyst target range
EPAM is covered by 17 analysts with a distribution of 8 Buy, 11 Hold, and 0 Sell ratings, yielding a consensus recommendation of "buy" with a recommendation mean of 2.21 (where lower is more bullish). The average target price is $128.71, which implies approximately -6.8% downside from the current price of $138.17, meaning the stock has already rallied past the consensus target and the consensus leans cautiously neutral-to-bullish rather than aggressively bullish. This is a notable signal: after a 27.59% one-month rally, the stock is trading above the average analyst target, suggesting either that analysts are lagging the price action or that the recent move is ahead of fundamentals.
The target range is wide, from a low of $97.00 to a high of $200.00, a spread of more than 2x that signals high uncertainty and divergent views on the AI disruption question. The high target of $200.00 implies roughly 45% upside and would require multiple expansion plus evidence that AI is a tailwind rather than a threat, along with a return to double-digit growth and margin recovery; the low target of $97.00 implies about 30% downside and prices in continued growth deceleration, margin compression, and competitive share loss. Institutional ratings show recent stability with some caution: JP Morgan downgraded from Overweight to Neutral on August 26, 2026, while Guggenheim reiterated Buy on November 2, 2026, and Citigroup and Wells Fargo maintained Neutral and Overweight respectively in late October, indicating that analysts are divided and the recent rally has not yet been validated by broad-based upgrades.
Drowning in data?
Find the real signal!
Bulls vs Bears: EPAM Investment Factors
The bear case currently has stronger near-term evidence: margins are compressing on every line, growth has decelerated to 4.53%, free cash flow has turned negative for two consecutive quarters, and the stock has already rallied 27.59% in a month to trade 6.8% above the consensus target. The bull case rests on a forward PE of 9.85x, a pristine balance sheet with debt-to-equity of 0.039, and a technical reversal off the $73 low that has delivered 29.58% relative strength versus SPY over one month. The single most important tension is whether generative AI is a tailwind that reaccelerates transformation spend or a structural threat to headcount-based IT services billing — if the forward EPS of $15.05 proves credible the stock is deeply undervalued, but if AI compresses billable hours the 9.85x multiple is a value trap. Until the next earnings report validates either the margin recovery or the growth stabilization, the risk/reward is balanced but the burden of proof sits with the bulls given the price now exceeds analyst targets.
Bullish
- Deep-value forward multiple at 9.85x: Forward PE of 9.85x against a trailing PE of 30.31x implies the market expects forward EPS of $15.05 versus a depressed trailing figure, and if even a portion of that recovery materializes the stock is among the cheapest quality names in IT services. The PS ratio of 2.10x and EV/Sales of 1.16x sit roughly 86% below the 14.84x PS the stock commanded in Q4 2023.
- Pristine balance sheet, minimal leverage: Debt-to-equity is just 0.039 and the current ratio is 2.59, with $794.3 million of cash at the end of Q2 2026. This gives EPAM the liquidity to keep funding the buyback ($324.0 million in Q1, $85.0 million in Q2) and to absorb a prolonged demand slowdown without solvency risk.
- Violent momentum reversal off capitulation low: The stock is up 27.59% over one month and 32.55% over six months, with relative strength versus SPY of +29.58% (1-month) and +29.44% (6-month), following a June 2026 low near $73-$76. The sequence of higher lows culminating in a push to $143.80 on November 2 is a classic early-stage trend-reversal signature rather than a dead-cat bounce.
- Revenue stable, not contracting: Q2 2026 revenue of $1.415 billion grew 4.53% year-over-year and rose sequentially from $1.400 billion in Q1, $1.408 billion in Q4 2025 and $1.394 billion in Q3 2025. The flat-to-up sequential progression across four quarters argues the business is holding its base even as headline growth decelerates.
Bearish
- Price has overshot the consensus target: At $138.17 the stock trades roughly 6.8% above the $128.71 average analyst target after a 27.59% one-month rally, meaning the move is ahead of published fundamentals. The target range of $97.00 to $200.00 is a spread of more than 2x, signaling unusually high uncertainty about the core AI question.
- Margins compressing across every line: Gross margin fell to 30.36% in Q2 2026 from 34.56% in Q3 2024, operating margin compressed to 10.76% from 15.16%, and net margin dropped to 7.28% from 11.68%. Trailing twelve-month net margin of 6.92% and operating margin of 9.55% are below the company's historical norms, reflecting wage inflation and pricing pressure.
- Growth decelerated to mid-single digits: Revenue growth of 4.53% year-over-year in Q2 2026 is a marked slowdown from the double-digit pace EPAM historically delivered, and the weak 2026 guidance triggered a 16% single-week selloff. The deceleration is the core of the bear case and the reason the stock is down 31.07% year-to-date versus the S&P 500's +10.62%.
- Negative free cash flow and heavy buybacks: Q2 2026 free cash flow was -$17.6 million and Q1 2026 was -$54.2 million, driven by working capital outflows of -$182.7 million and -$229.6 million respectively, while the company repurchased $409.0 million of stock across the two quarters. Funding buybacks while burning cash raises questions about capital allocation discipline.
EPAM Technical Analysis
EPAM is in a recovery phase within a longer-term downtrend, with the stock down 14.56% over the past year and 31.07% year-to-date, a stark underperformance versus the S&P 500's +10.39% 1-year and +10.62% YTD returns. At the current price of $138.17, the stock sits at approximately 43.7% of its 52-week range of $73.06 to $222.53, meaning it has recovered meaningfully off the lows but remains far below the highs, consistent with a market that has repriced the growth story downward rather than abandoned it. The maximum drawdown of -65.65% underscores how violent the de-rating has been, and the current positioning suggests the stock is neither an overextended momentum name nor a falling knife, but a contested recovery candidate.
Short-term momentum is decisively positive and sharply divergent from the 1-year trend: the stock is up 27.59% over the past month, 25.76% over three months, and 32.55% over six months, with relative strength versus SPY of +29.58% (1-month), +27.77% (3-month), and +29.44% (6-month). This acceleration follows a capitulation low near $73-$76 in June 2026, and the sequence of higher lows since then, culminating in a push to $143.80 on November 2 before a -3.92% pullback to $138.17, suggests the market is repricing the stock higher on improving sentiment rather than merely mean-reverting. The divergence between the negative 1-year return and the strongly positive 1-month and 3-month returns is a classic early-stage trend-reversal signature, though the single-day -3.92% drop and elevated short ratio of 6.51 indicate the move is crowded and vulnerable to sharp reversals.
Key technical levels are well defined: support sits at the 52-week low of $73.06, with intermediate support likely in the $110-$115 zone where the stock consolidated in September and October 2026, while resistance is anchored at the 52-week high of $222.53, far above current levels, with nearer-term resistance around the recent $143.80 high. A breakout above $143.80 would signal confirmation of the recovery and likely open a path toward the $160-$170 area, whereas a breakdown below $110 would suggest the October rally was a failed bounce and refocus attention on the $73 low. With a beta of 1.266, EPAM is roughly 27% more volatile than the market, meaning position sizing should account for amplified drawdowns, and the 6.51 short ratio implies squeeze potential on upside surprises but also crowded positioning risk.
Beta
1.27
1.27x market volatility
Max Drawdown
-65.7%
Largest decline past year
52-Week Range
$73-$223
Price range past year
Annual Return
-13.3%
Cumulative gain past year
| Period | EPAM Return | S&P 500 |
|---|---|---|
| 1m | +24.9% | -1.0% |
| 3m | +47.6% | -0.2% |
| 6m | +38.4% | +4.0% |
| 1y | -13.3% | +13.6% |
| ytd | -31.5% | +12.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EPAM Fundamental Analysis
EPAM's revenue trajectory is one of steady but decelerating growth: Q2 2026 revenue of $1.415 billion grew 4.53% year-over-year, a marked slowdown from the double-digit growth the company historically delivered, and the multi-quarter trend shows revenue essentially flat sequentially ($1.400B in Q1 2026, $1.408B in Q4 2025, $1.394B in Q3 2025, $1.353B in Q2 2025). Segment data shows Financial Services as the largest vertical at $366.2 million, followed by Consumer Goods, Retail & Travel at $274.3 million, Emerging Verticals at $236.5 million, Software and Hi-Tech at $202.0 million, Healthcare at $169.1 million, and Business Information and Media at $166.7 million, indicating a diversified but financially-services-heavy mix that is exposed to client discretionary spend cycles. The deceleration to mid-single-digit growth is the core of the bear case and explains the stock's de-rating, though the stability of sequential revenue suggests the business is not contracting.
Profitability remains solid but is compressing: Q2 2026 net income was $102.98 million with a net margin of 7.28%, down from 11.68% in Q3 2024, while gross margin fell to 30.36% from 34.56% in Q3 2024 and 30.44% in Q4 2024, and operating margin compressed to 10.76% from 15.16% in Q3 2024. The compression reflects wage inflation, pricing pressure, and a mix shift toward lower-margin work, and the trailing twelve-month net margin of 6.92% and operating margin of 9.55% are below the company's historical norms for this industry. The company remains profitable with a trailing EPS of $0.03 on a reported basis (reflecting one-off items) but a quarterly diluted EPS of $1.97, and the forward EPS estimate of $15.05 implies the market expects a meaningful earnings recovery.
EPAM's balance sheet is a genuine strength: debt-to-equity is just 0.039, the current ratio is 2.59, and cash at the end of Q2 2026 was $794.3 million, providing substantial liquidity and minimal financial risk. However, cash flow quality has deteriorated sharply, with Q2 2026 free cash flow of -$17.6 million and Q1 2026 FCF of -$54.2 million, driven by working capital outflows (change in working capital of -$182.7 million in Q2 and -$229.6 million in Q1) and heavy buyback activity ($85.0 million in Q2, $324.0 million in Q1). The trailing twelve-month FCF of $482.6 million and ROE of 10.27% confirm the business can generate cash, but the recent negative quarters and aggressive repurchases raise questions about capital allocation discipline and near-term liquidity deployment.
Quarterly Revenue
$1.4B
2026-06
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
30.4%
Latest Quarter
Free Cash Flow
$482636000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EPAM Overvalued?
Because EPAM is profitable (Q2 2026 net income of $102.98 million), the PE ratio is the appropriate primary metric: the trailing PE is 30.31x while the forward PE is just 9.85x, an extraordinarily wide gap that implies the market expects earnings to more than triple, consistent with the forward EPS estimate of $15.05 versus the depressed trailing figure. The forward PE of 9.85x is remarkably low for a technology services company and suggests either significant skepticism about the earnings recovery or a genuine deep-value opportunity, while the PS ratio of 2.10x and EV/Sales of 1.16x indicate the market is valuing EPAM at a steep discount to its historical revenue multiples.
Peer comparison within Information Technology Services shows EPAM trading at a discount on most metrics: the PS ratio of 2.10x and EV/Sales of 1.16x are well below the 5x-10x range EPAM historically commanded and below many IT services peers, while the EV/EBITDA of 15.33x is moderate and the PB ratio of 3.11x is reasonable. The PEG ratio of -2.05 is not meaningful given negative earnings growth, but the forward PE of 9.85x versus a trailing PE of 30.31x implies a dramatic earnings inflection that, if delivered, would make EPAM one of the cheapest quality names in the sector. The discount appears to reflect genuine concerns about AI disruption and growth deceleration rather than a temporary dislocation, so the premium/discount debate hinges on whether the forward estimates are credible.
Historically, EPAM traded at far richer multiples: the PE ratio was 43.99x in Q4 2023, 32.12x in Q4 2024, and 25.74x in Q4 2025, while the PS ratio was 14.84x in Q4 2023, 10.64x in Q4 2024, and 8.00x in Q4 2025, meaning the current 2.10x PS and 30.31x trailing PE represent a multi-year low in valuation. The compression from 14.84x PS to 2.10x PS is a roughly 86% de-rating, placing the stock near the bottom of its own historical band and suggesting the market has priced in severe pessimism; whether this is a value opportunity or a value trap depends on whether revenue growth stabilizes and margins recover.
PE
30.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 10x~49x
vs. Industry Avg
19.1x
Industry PE ~19.1x*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin erosion and cash conversion. Gross margin has fallen from 34.56% in Q3 2024 to 30.36% in Q2 2026, operating margin from 15.16% to 10.76%, and net margin from 11.68% to 7.28%, a compression of roughly 400-440 basis points across each line in under two years. Free cash flow turned negative in both Q1 2026 (-$54.2 million) and Q2 2026 (-$17.6 million) as working capital swung out by -$229.6 million and -$182.7 million, even as the company deployed $409.0 million on buybacks in the same period. Revenue is also concentrated: Financial Services is the largest vertical at $366.2 million and North America is roughly 60% of revenue, leaving EPAM exposed to a single region's discretionary IT budgets. The forward EPS estimate of $15.05 versus a trailing EPS of $0.03 means the entire valuation depends on an earnings inflection that has not yet appeared in reported results.
Market and competitive risks are dominated by the AI disruption question and valuation uncertainty. The stock carries a beta of 1.266, so a 10% market decline would be expected to produce roughly a 12.7% drop, and the -65.65% maximum drawdown shows how severe the repricing can be when the growth narrative breaks. The analyst target range of $97.00 to $200.00 is a spread of more than 2x, and JP Morgan downgraded from Overweight to Neutral on August 26, 2026, while Citigroup and Wells Fargo stayed Neutral and Overweight respectively — a divided community that has not validated the recent rally with broad upgrades. The 16% single-week selloff in February 2026 after weak 2026 guidance, and the -3.92% single-day drop on November 3, illustrate how quickly sentiment can reverse. With a short ratio of 6.51, positioning is crowded and vulnerable to sharp unwinds.
The worst-case scenario is a chain in which AI-driven productivity gains compress billable headcount faster than EPAM can reprice, causing revenue growth to stall near zero while gross margin slides below 30%, forcing further downward estimate revisions and a re-rating toward the low end of the historical band. In that path the stock would retest the 52-week low of $73.06, roughly 47% below the current $138.17, and could approach the analyst low target of $97.00 (about 30% downside) even in a milder version. A realistic adverse outcome is a decline to the $97-$110 support zone, a loss of 20% to 30%, with a tail scenario down to $73 representing a 47% drawdown from today's price.
FAQ
The most severe risk is margin erosion: gross margin has fallen to 30.36% from 34.56% in Q3 2024, operating margin to 10.76% from 15.16%, and net margin to 7.28% from 11.68%, and a break below 30% gross margin would likely trigger estimate cuts and a re-rating toward the $97 analyst low. Second is cash flow quality, with free cash flow negative in both Q1 2026 (-$54.2 million) and Q2 2026 (-$17.6 million) on working capital outflows of -$229.6 million and -$182.7 million even as $409.0 million was spent on buybacks. Third is the AI disruption question: if generative AI compresses billable headcount faster than EPAM can reprice, the 4.53% revenue growth could stall toward zero, making the 9.85x forward multiple a value trap. Fourth is market and positioning risk, with a beta of 1.266, a short ratio of 6.51, a -65.65% historical max drawdown, and a demonstrated -3.92% single-day drop on November 3 showing how violently sentiment can reverse.
The 12-month forecast is split roughly evenly around a muddle-through center. The base case carries 50% probability with a $115-$140 range, assuming revenue growth holds in the 3%-6% band, gross margin stays near 30%-31%, free cash flow turns positive, and the forward PE holds in an 8x-10x band around the $128.71 consensus target. The bull case carries 25% probability with a $160-$200 range, requiring AI to prove a demand tailwind, gross margin recovery above 32%, revenue reacceleration above 6%, and a re-rating to 11x-13x forward earnings. The bear case carries 25% probability with a $73-$97 range, driven by gross margin breaking below 30%, a third negative free cash flow quarter, and further guidance cuts. The base case is most likely, and its key assumption is that the revenue base holds flat sequentially as it has for four quarters while margins stabilize rather than deteriorate further.
On forward earnings EPAM looks undervalued, but on price after the recent rally it looks closer to fairly valued. The forward PE of 9.85x versus a trailing PE of 30.31x implies forward EPS of $15.05 against a depressed trailing figure, and the PS ratio of 2.10x and EV/Sales of 1.16x sit roughly 86% below the 14.84x PS the stock commanded in Q4 2023 — a multi-year low in the valuation band. The PB ratio of 3.11x and EV/EBITDA of 15.33x are moderate rather than distressed. However, the stock at $138.17 is 6.8% above the $128.71 average analyst target, meaning the market has already priced in a good deal of the recovery. The valuation implies the market expects earnings to more than triple, and whether that is a discount or a value trap depends entirely on whether the forward EPS estimate is credible.
From a risk/reward standpoint, EPAM is a reasonable but not compelling buy at $138.17. The upside case rests on a 9.85x forward PE and a pristine balance sheet (debt-to-equity of 0.039, $794.3 million of cash), with the $200 analyst high target implying roughly 45% upside if AI proves a tailwind and margins recover. The problem is that the stock has already rallied 27.59% in a month and trades about 6.8% above the $128.71 consensus target, so near-term upside to the average target is negative. The biggest downside risk is a margin break below 30% that sends the stock toward the $97 analyst low (about 30% downside) or the $73.06 52-week low (about 47% downside). It is a good buy for patient, risk-tolerant investors who can wait 12-24 months for the earnings inflection and who size positions for a beta of 1.266, and a better buy on a pullback toward the $110-$115 consolidation zone.
EPAM is better suited to a long-term hold than to short-term trading, though its volatility makes it a difficult position to sit through. The company is in a mature-but-contested growth stage: revenue grew only 4.53% year-over-year in Q2 2026, but the business generates $482.6 million of trailing twelve-month free cash flow and a 10.27% ROE, and the balance sheet carries essentially no leverage. There is no dividend (0% yield, 0 payout ratio), so total return depends entirely on earnings recovery and multiple re-rating. The beta of 1.266, the 6.51 short ratio and the -65.65% max drawdown mean short-term price action is dominated by sentiment and positioning rather than fundamentals, as the -3.92% single-day drop on November 3 and the 16% single-week selloff in February 2026 demonstrate. A concrete minimum holding period of 12-24 months is appropriate, giving the company at least four to six quarters to prove the forward EPS of $15.05 and to show gross margin stabilization above 30% with positive free cash flow.